Sensitivity of Candida albicans isolates to caspofungin - Comparison of microdilution method and E-test procedure

Archives of Medical Science

Volumn 5, Issue 1, 2009, Pages 23-27

  Serefko, Anna ^a   Malm, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Candida albicans; Caspofungin; E test; Minimal fungicidal concentration; Minimal inhibitory concentration

Indexed keywords

CASPOFUNGIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; EPSILOMETER TEST; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TURBIDITY;

EID: 65549169531     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kulemann V, Bauer M, Graninger W, Joukhadar C. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology 2005; 75: 165-78.
2. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23: 1093-7.
3. Randhawa GK, Sharma G. Echinocandins: A promising new antifungal group. Indian J Pharmacol 2004; 36: 65-71.
4. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-21.
5. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microb 2002; 40: 3841-4.
6. CLSI - Clinical and Laboratory Standards Institute. NCCLS document M27-A2. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard - Second Edition. 2002, Wayne, Pennsylwania, USA.
7. Laverdiere M, Restieri C, Habel F. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int J Antimicrob Agents 2002; 20: 468-71.
8. Pujol I, Aguilar C, Fernández-Ballart J, Guarro J. Comparison of the minimum fungicidal concentration of amphotericin B determined in filamentous fungi by macrodilution and microdilution methods. Med Mycol 2000; 38: 23-6.
9. Barry AL, Pfaller MA, Brown SD, et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2000; 38: 3457-9.
10. Bartizal C, Odds FC. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47: 2100-7.
11. Bachmann SP, Patterson TF, López-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microb 2002; 40: 2228-30.
12. Yang YL. Virulence factors of Candida species. J Microbiol Immunol Inf 2003; 36: 223-8.
13. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microb 1998; 36: 2950-6.
14. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazoleresistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-71.
15. Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microb 2003; 41: 5729-31.
16. Biernasiuk A, Korona-Glowniak I, Mahorowska-Kiciak I, Rybojad P, Malm A. Pharyngeal Candida sp. strains in patients with non-small cell lung cancer. Mikol Lek 2006; 13: 89-93.
17. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998; 31: 33-7.
18. Arévalo MP, Carrillo-Muñoz AJ, Salgado J, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003; 51: 163-6.
19. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002; 46: 3846-53.
20. Pfaller MA, Messer SA, Boyken L, et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol 2004; 42: 3117-9.
21. Pfaller MA, Messer SA, Mills K, Bolmström A, Jones RN. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microb 2001; 39: 4387-9.
22. Arikan S, Sancak B, Hascelik G. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol 2005; 43: 171-8.
23. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50: 1293-7.
24. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407-11.
25. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49: 5146-8.